For both human (HIV) and simian (SIV) immunodeficiency viruses, vaccines have failed to generate antibodies that can cross-neutralize genetically divergent isolates. Moreover, with the exception of an attenuated SIV, these preparations have generally failed to produce protective immune responses in animal models. One possible explanation for this failure has been that synthetic, recombinant or killed virus preparations utilized to date have not preserved the structural integrity of viral envelope glycoproteins present on virions and infected cells. Interestingly, recent studies of HIV-1 have indicated that when soluble oligomeric rather than monomeric envelope glycoproteins are used as immunogens, neutralizing antibodies can be produced whose epitopes are defined by the quaternary structure of this multimeric complex. This finding has indicated that there are potentially important components of the humoral immune response to HIV that become evident only when envelope glycoproteins are presented to the immune system in their native multimeric conformation, and which have not been examined thus far. As will be described, these observations have recently been extended to an in vitro SIV model in which an SIV was genetically altered to express increased levels of conformationally-intact envelope glycoproteins on the surface of infected cells. When these cell- associated envelope molecules were used as an immunogen in mice, a novel panel of monoclonal antibodies was produced that exhibited potent and cross-neutralizing activity for several genetically divergent isolates of SIV. These preliminary findings have indicated that similar to HIV-1, SIV envelope glycoproteins can also elicit a strong and broadly-reactive neutralizing immune response when their native multimeric conformation is maintained. Clearly, a thorough evaluation of this humoral response is needed for SIV where its relevance to protective immunity can be determined. This proposal will rigorously assess the humoral immune response to novel preparations of soluble and cell-associated oligomeric envelope glycoproteins of SIV in both small animal and non-human primate models. Specifically, plans are described, 1) to produce and characterize soluble and membrane-associated oligomeric SIV envelope molecules as immunogens; 2) to produce monoclonal and polyclonal antibodies to these immunogens in order to characterize their antigenic structure and to determine their ability to elicit neutralizing antibodies to genetically divergent isolates; and 3) to analyze the humoral responses in non-human primates and determine if protection can be achieved from a viral challenge. These studies will add considerably to an understanding of the contribution of envelope glycoprotein quaternary structure to its immunogenicity and determine its potential use in developing an effective vaccine for HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI038225-04
Application #
2672531
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1995-06-01
Project End
1999-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bowers, K; Pelchen-Matthews, A; Honing, S et al. (2000) The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 1:661-74
Hoffman, T L; Doms, R W (1999) HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 16:57-65
Berson, J F; Doms, R W (1998) Structure-function studies of the HIV-1 coreceptors. Semin Immunol 10:237-48
Samson, M; Edinger, A L; Stordeur, P et al. (1998) ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 28:1689-700
Signoret, N; Rosenkilde, M M; Klasse, P J et al. (1998) Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci 111 ( Pt 18):2819-30
Lee, B; Doranz, B J; Ratajczak, M Z et al. (1998) An intricate Web: chemokine receptors, HIV-1 and hematopoiesis. Stem Cells 16:79-88
Cho, M W; Lee, M K; Carney, M C et al. (1998) Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 72:2509-15
Horuk, R; Hesselgesser, J; Zhou, Y et al. (1998) The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 273:386-91
Hoffman, T L; MacGregor, R R; Burger, H et al. (1997) CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J Infect Dis 176:1093-6
Doranz, B J; Berson, J F; Rucker, J et al. (1997) Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 16:15-28

Showing the most recent 10 out of 20 publications